(Incorporated in Delaware)

We are a medical device company preparing to commercialize breakthrough computerized analysis technology that enhances clinicians’ capabilities in diagnosing neurological and neurodevelopmental disorders. NSI’s first product, GyriCalc™ is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated measurement and analysis of MRI images. GyriCalc delivers objective, data-driven results that we believe have the potential to dramatically shorten the time to diagnosis, accelerating access to critical therapeutic interventions. Although GyriCalc has received FDA 510(k) marketing clearance, GyriCalc has not yet received FDA clearance for diagnostic use.

Currently, NSI does not generate any revenue. Our primary focus is on successfully launching GyriCalc for autism and establishing a foothold in the U.S. and Canadian markets.

GyriCalc currently focuses on autism. This proprietary, patented software technology identifies early human brain structural markers of neurodevelopmental differences by automatically analyzing images taken by magnetic resonance imaging (MRI) machines. Academic laboratory research with this type of technology at the University of Louisville has suggested the technology could potentially be applied to such conditions as dyslexia, ADHD, or schizophrenia. The Company has no plans regarding these other conditions at this time. The development, approval, and commercialization of any successor product are subject to significant clinical, regulatory, and operational risks, and actual timelines are uncertain.

(Note: Neuro Spectrum Insights, Inc. filed terms for its small IPO – 3.75 million shares at a price range of $4.00 to $5.00 – to raise $16.88 million, if priced at the $4.50 mid-point of its range. Background: Neuro Spectrum Insights filed its S-1 on June 18, 2026.)